(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Novavax will ...
Shares of Novavax surged after the company disclosed a $1.4 billion licensing deal with Sanofi. The stock was up 72% at $7.66 in premarket trading on Friday. Shares are on track to open in ...
LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...
Don’t call it a comeback: Novavax just (briefly) became a meme stock. The Maryland-based biotech joined the likes of Ango American, Vodafone and the notorious GameStop in a resurgence of the meme ...
Shares of Novavax jumped as much as 50% as Wall Street cheered a new multibillion-dollar deal with French drugmaker Sanofi that kicked off a dramatic turnaround for the struggling vaccine maker.
Shares of Novavax, Inc. NVAX skyrocketed nearly 99% on Friday after announcing a multi-billion-dollar deal with pharma giant Sanofi SNY for its protein-based COVID-19 vaccine, Nuvaxovid.
May 20 (Reuters) - Hedge fund Shah Capital said on Monday it would withdraw its campaign against the re-election of three directors on Novavax's (NVAX.O) , opens new tab board, after the COVID-19 ...